Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
CASE REPORTS
Nanoparticle Albumin-bound Paclitaxel+Carboplatin Therapy for Small Cell Lung Cancer Combined with Squamous Cell Carcinoma and Interstitial Lung Disease
Yuichiro AzumaMotohiro TamiyaTakayuki ShiroyamaAkio OsaSawa TakeokaNaoko MorishitaHidekazu SuzukiNorio OkamotoTomonori HirashimaIchiro Kawase
Author information
JOURNALS OPEN ACCESS

2015 Volume 54 Issue 22 Pages 2911-2913

Details
Abstract

It has recently been shown that nanoparticle albumin-bound paclitaxel (nab-PAC)+carboplatin (CBDCA) provides a favorable overall response rate in non-small cell lung cancer. This is the first case report of nab-PAC+CBDCA therapy in small cell lung cancer (SCLC). Our patient was a 72-year-old man with stage IV SCLC combined with squamous cell carcinoma and interstitial lung disease (ILD). We administered nab-PAC+CBDCA as a second-line chemotherapy. A partial response was evident after two cycles of chemotherapy, and no serious side effects occurred. The progression-free survival was 15 weeks. Second-line chemotherapy using nab-PAC+CBDCA was effective and well tolerated in an SCLC patient with ILD.

Information related to the author
© 2015 by The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top